President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

The Centers for Medicare and Medicaid Services (CMS) listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of its list of drugs selected for Medicare negotiation in 2025.

Some 2.3 million Medicare enrollees use Ozempic, Wegovy, and Rybelsus combined, and Medicare spent $14.3 billion buying them between November 2023 and October 2024, according to the Centers for ...

After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price ...

The Centers for Medicare and Medicaid Services says the 15 drugs are Ozempic, Rybelsus and Wegovy; Trelegy Ellipta; Xtandi; Pomalyst; Ibrance; Ofev; Linzess; Calquence; Austedo and Austedo XR ...

The CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top of the list of drugs for which Medicare will the negotiate the price of in 2025. The list price for a one ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and ...